Use of the Mst protein for the treatment of a thromboembolic disorder

Details for Australian Patent Application No. 2006226627 (hide)

Owner Sanofi-Aventis

Inventors Rueck, Alexander; Concari, Paola; Herrmann, Matthias; Leeuw, Thomas; Kruip, Jochen

Agent Watermark

Pub. Number AU-B-2006226627

PCT Pub. Number WO2006/100021

Priority 05006359.3 23.03.05 EP

Filing date 20 March 2006

Wipo publication date 28 September 2006

Acceptance publication date 22 December 2011

International Classifications

A61K 38/45 (2006.01) Medicinal preparations containing peptides

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

18 October 2007 PCT application entered the National Phase

  PCT publication WO2006/100021 Priority application(s): WO2006/100021

22 December 2011 Application Accepted

  Published as AU-B-2006226627

3 May 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  Application withdrawn under section 141(1). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006226635-Adjusting apparatus for a pneumatically actuated disc brake

2006226625-Polymorphic form of 6- (4-chlorophenyl) -2, 2-dimethyl-7-phenyl-2, 3-dihydro-lH-pyrrolizin-5-ylacetic acid